Adaptimmune Therapeutics (ADAP) Tops Q3 EPS by 14c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.03), $0.14 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $14.41 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• Evommune, Inc. (EVMN) Misses Q2 EPS by 20c
• Atlassian results seen as 'game changer' for AI kills software worries